38 results about "Bortezomib" patented technology

The invention relates to the technical field of medicine preparation, and provides a bortezomib nano composition, and the bortezomib nano composition comprises the following components: bortezomib, albumin and a medium. The bortezomib nano composition can be delivered in a targeted manner, is low in toxicity and stable, and provides a new strategy for treatment of multiple myeloma.

Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.

The invention provides an application of gastrodin in preparation of a medicine for treating peripheral neuropathy. According to the application disclosed by the invention, gastrodin can inhibit neuroinflammation mediated by microglia by inhibiting activation of an NF-kB / NLRP3 inflammasome signal channel, so that release of inflammatory factors is reduced, and neuropathy induced by bortezomib is relieved.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The present invention relates to a pharmaceutical composition comprising mitogens and stress control pathway inhibitors for the treatment of cancer. The present invention more specifically relates to a pharmaceutical composition comprising FGF-2 and bortezomib or LB-100 and bortezomib for the treatment of cancer cells without compromising the survival of normal cells.

The present invention belongs to the technical field of drug carriers, and particularly relates to a nano-gel drug delivery system loaded with bortezomib and a preparation method thereof. The present invention uses a gelatin-dopamine (Gel-Dopa) complex and oxidized hyaluronic acid (OHA) as substrates to construct a nano-gel-based drug delivery system loaded with the chemotherapeutic drug BTZ. According to the characteristics of low pH in tumor tissues and overexpression of MMP-2 enzyme, a nano-gel with dual sensitivity to pH and MMP-2 enzyme is designed, and at the same time, the active targeting ability of HA is combined to improve the delivery efficiency of BTZ to tumor tissues, reduce the toxic and side effects of BTZ on normal cell tissues, and achieve controlled release of the drug.

This invention provides the application of the IFI16 gene as a target in the preparation of bortezomib-resistant drugs for the treatment of multiple myeloma, involving drug targets, related diagnostic reagents, and treatment strategies for the diagnosis and treatment of multiple myeloma (MM). This invention reveals for the first time the core driving role of IFI16 in bortezomib resistance in MM and its novel mechanism of action through the Wnt / β-catenin pathway; more importantly, it provides novel biomarkers, drug targets, and highly feasible combination therapy regimens for accurate prognostic assessment of MM and overcoming the clinically challenging problem of bortezomib resistance, possessing significant theoretical implications and broad clinical application prospects.

The invention belongs to the field of medical injection, and discloses a multi-section myeloma targeted therapy injection device which comprises a support, a lifting device fixedly arranged above the support, a clamping device fixedly arranged above the lifting device, a placing device fixedly arranged below the support, and a medicine bottle movably arranged in the placing device. An injection tube is movably arranged on one side of the lifting device and the clamping device, a push rod is movably arranged on the inner wall of the injection tube, a needle is embedded below the injection tube, and an adjusting device is arranged on the inner wall of the push rod in a threaded fit mode; the device solves the problems that when an existing targeted therapy device injects bortezomib, in the liquid medicine injection process, sectional injection is difficult to conduct on liquid medicine, injection amount precision control is poor during manual injection, and the therapeutic effect is affected, and is suitable for myeloma targeted therapy injection.

This invention provides the application of indexsulfanilamide in the preparation of drugs for the prevention and / or treatment of multiple myeloma, belonging to the field of oncology drug technology. Indexsulfanilamide exhibits significant anti-multiple myeloma effects in various multiple myeloma cell lines, primary cells, and multiple myeloma mouse models, and inhibits tumor growth in multiple myeloma mice while demonstrating good safety. Furthermore, the combination of indexsulfanilamide and bortezomib produces a synergistic effect, suggesting that indexsulfanilamide has a promising therapeutic prospect for multiple myeloma.

The present invention relates to the field of biomedicine, and in particular to a nanobody conjugate, its preparation method, and application. The nanobody conjugate comprises a conjugated antibody fusion protein and bortezomib; the antibody fusion protein is a fusion protein of an elastin-like polypeptide and an anti-Her2 nanobody. The nanobody conjugate of the present invention can improve the stability and enzyme selectivity of bortezomib, reduce the drug's toxic side effects, and simultaneously achieve tumor targeting effects by combining tumor-specific nanobody targeting technology. It can be used to treat cancers with high Her2 expression, and has excellent value and potential for widespread application.

The invention relates to the technical field of medicines, in particular to a covalent organic framework material loaded with a boron drug compound as well as a preparation method and application of the covalent organic framework material. The covalent organic framework material loaded with the boron drug compound comprises bortezomib and a loading body, and the loading body is prepared from a covalent organic framework material modified by folic acid. The pore size regulation of the triazinyl COF is matched with the molecular size of the boron drug, and the topological structure design (AA stacking mode) of the COF is combined with the dynamic simulation of drug molecules, so that the ultrahigh drug loading capacity (42.7%) and the high retention rate gt of the drug within 72 hours are realized; moreover, folic acid molecules are connected through thioether bonds, so that gt is realized while the COF crystallinity is kept; and the FA surface coverage rate is 85%. The three-in-one design of'structure adaptive drug loading, chemical stable targeting and accurate environment release 'is realized for the first time, an efficient drug delivery platform is provided for advanced therapies such as boron neutron capture therapy (BNCT) and the like, and cross development of anti-cancer drugs from'extensive chemotherapy' to'molecular-level accurate regulation and control 'is promoted.

The invention discloses an application of a CaMKII-gamma inhibitor serving as a bortezomib-resistant multiple myeloma treatment medicine. On the basis of si-RNA, cell proliferation activity can be inhibited by down-regulating expression of CaMKII-gamma in bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, a small molecule compound rucotinib capable of effectively inhibiting activity of CaMKII-gamma kinase is obtained through high-throughput screening, growth of multiple myeloma U266 cells and KMS11 cells can be obviously inhibited, and the activity of the rucotinib can be effectively inhibited. The compound has an obvious inhibition effect on the growth of bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, also has an obvious inhibition effect on the growth of U266.BR transplantation tumors, and shows a good tumor inhibition effect as a potential medicine for treating multiple myeloma and bortezomib-resistant multiple myeloma.

The invention belongs to the field of biological medicines, and particularly relates to application of a compound to preparation of a medicine for treating papilloma of the upper respiratory tract. The invention provides an application of a compound in preparation of a medicine for treating and / or preventing papilloma of the upper respiratory tract, and is characterized in that the compound comprises one or more of asperisib, crizotinib, lapatinib, osimertinib and bortezomib. Experimental results show that the asperisib, crizotinib, lapatinib, osimertinib and bortezomib can realize long-term control on the papilloma of the upper respiratory tract and reduce the recurrence risk of the papilloma of the upper respiratory tract to a certain extent, so that the life quality of patients with the papilloma of the upper respiratory tract can be improved; the invention has important scientific value and clinical application prospect in the field of upper respiratory papilloma treatment.

Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenstrom's Macroglobulinaemia (WM), providing the rationale for investigating the combination.Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III / IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status ≥1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3 mg / m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375 mg / m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6 mg / m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375 mg / m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO 17:1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood 107:3442, 2006)Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm B. Haematological toxicity (grade≥3: anaemia 0%, neutropenia 25%, thrombocytopenia 22%) was significantly influenced by the high percentage of pts. with BM infiltration and concomitant cytopenia on entry to the trial. The most common non-haematological adverse events were fatigue (76%), nausea (56%), diarrhoea (56%), lethargy (46%). Neurotoxicity occurred in 19 pts. (46%) (10 pts. grade 1, 7 pts. grade 2, 2 pts. grade 3). Btz dose was reduced in 7 pts.; 5 doses were omitted because of neuro or haematological toxicity. In 16 pts., treatment was delayed by 1-14 days and in 24 pts. treatment was stopped prematurely. The reasons for stopping treatment were: treatment-related toxicity 11 pts., progressive disease 9 pts., patient's preference 3 pts., myocardial infarction 1 pt. One pt. was excluded having been found ineligible post randomisation. Thirty-nine pts. (21 arm A, 18 arm B) are evaluable for response so far, one having only received 1 cycle of therapy, which had to be discontinued because of excessive toxicity. 15 / 32 were in remission (CR, CRu, PR) at the completion of therapy, 7 / 7 at “mid-therapy” assessment, and 5 have yet to be evaluated. Thus the overall response rate (RR) presently is 22 / 39 (56%) (CR, CRu, PR), FL 44%, MCL 46%, WM 90%.Conclusions:The combination was active in pts. with recurrent NHL especially WM (RR 90%), despite multiple previous treatments, The weekly schedule is preferable being more convenient, as efficacious and no more toxic.Further investigation is warranted, despite not insignificant therapy compromising toxicity.

The invention discloses a bortezomib and illicit loaded targeted copper / calcium bimetal-based nanocage and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out in-situ etching on amorphous calcium carbonate nanospheres by using a copper chloride aqueous solution to form the copper / calcium bimetal-based nanocage; the preparation method comprises the following steps: loading bortezomib and illicit in a nanocage under the coordination action to form a bortezomib and illicit loaded copper / calcium bimetal-based nanocage; and then carrying out surface modification by using hydrazide hyaluronic acid to form the bortezomib and illicit loaded targeted copper / calcium double-metal-based nanocage capable of specifically acting with cancer cells. The copper / calcium bimetal-based nanocage has the structural characteristics of large specific surface area, moderate particle size and pore size, capability of coordinating and combining a plurality of groups and the like, is high in drug loading capacity, and has pH / glutathione dual responsiveness and Fenton-like catalytic reaction characteristics. According to the invention, the bortezomib and the illicit are loaded in the nanocage through coordination, and the drug loading rates respectively reach 13.9% and 31.7%; the final nanocage has a tumor targeting function and can efficiently trigger cancer cell endoplasmic reticulum stress and nematode damage, and the synergistic amplification effect of the two can significantly enhance the immunotherapy effect.

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and / or Ibrutinib.

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

This application provides a pharmaceutical composition and its application for treating liver cancer, relating to the field of biomedical technology. The pharmaceutical composition includes active ingredients, namely the proteasome inhibitor Bortezomib and the Rev-Erb agonist SR9009. By combining the proteasome inhibitor Bortezomib with the Rev-Erb agonist SR9009, synergistic anti-liver cancer activity is observed both in vitro and in vivo, enhancing the mechanism of protein toxicity-induced apoptosis in liver cancer cells. The combined effect of Bortezomib and Rev-Erb agonist SR9009 is significantly superior to either Bortezomib or Rev-Erb agonist alone, overcoming the poor efficacy of Bortezomib monotherapy in liver cancer, and demonstrating significant synergistic effects and clinical application value.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention discloses a medicine for treating multiple myeloma by combining an arginine methyltransferase 5 inhibitor and bortezomib. The invention creatively discloses the synergistic effect of the PRMT5 inhibitor and BTZ combined application in the anti-MM medicine or the medicine composition. The combined medication scheme shows remarkable synergistic anti-tumor activity in vitro and in vivo, the average ZIP synergistic fraction is larger than 10 and is far higher than single drug simple superposition, proliferation of MM cells can be effectively inhibited, cell apoptosis is induced, and the BTZ treatment effect is remarkably improved.

A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of Bortezomib, Ibrutinib or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein. The cancer may be refractory to Bortezomib and / or Ibrutinib

Described herein are liquid compositions comprising: bortezomib; mannitol in an amount up to about 50 mg / mL; and a pharmaceutically acceptable carrier, wherein the liquid composition is for intravenous or subcutaneous use; and wherein the liquid composition comprises not more than (NMT) 1.0% of Impurity-E; Impurity-L; Impurity-J; Impurity-F; Impurity-I; or Impurity-U; and NMT than 3.0% of Total Impurities. Methods of making and using these compositions are also described herein.

This invention relates to the field of pharmaceutical preparations, specifically to a method for preparing a lyophilized bortezomib for injection. The method for preparing a lyophilized bortezomib for injection provided by this invention includes preparing bortezomib mannitol ester and preparing a lyophilized bortezomib for injection. The preparation of bortezomib mannitol ester includes the following steps: adding mannitol to purified water and stirring to dissolve it to form a mannitol solution; adding tert-butanol to the mannitol solution and stirring until homogeneous to form a mixture; adding bortezomib to the resulting mixture and stirring until completely dissolved to form a bortezomib mannitol ester solution; filtering the resulting bortezomib mannitol ester solution, dispensing the filtrate into stainless steel trays, and placing them in a lyophilization chamber; lyophilizing, collecting the lyophilized powder, and obtaining bortezomib mannitol ester. This invention effectively overcomes the problems of foreign matter in lyophilized bortezomib preparations and poor clarity after reconstitution.

A method of administering bortezomib into a brain tumor by a pump implanted in a brain of a subject. The method includes administering a drug to a tumor in a central nervous system of a subject, the method comprising, delivering a therapeutically effective amount of the drug into a brain, tumor by a pump implanted in a brain of the subject, wherein administration of the drag to the subject in the central nervous system is contraindicated because of toxicity of the drug.

The present invention discloses a bortezomib-based small molecule nano-drug, its preparation method and application, belonging to the field of pharmaceutical technology. In the present invention, bortezomib and guanosine are added to an organic solvent, an alkali reagent and anhydrous sodium sulfate are added, and the mixture is reacted evenly. After completion, rotary evaporation is carried out to obtain a white solid product, the bortezomib-guanosine conjugate drug; the above-mentioned bortezomib-guanosine conjugate drug is dissolved in tetrahydrofuran, and then water is slowly added dropwise, stirred for a period of time, and transferred to continue stirring under a fume hood to obtain the bortezomib-guanosine nano-drug. The nano-drug of the present invention can achieve self-administration without the aid of a carrier. By avoiding the use of an additional carrier, the prepared small molecule nano-drug has the advantages of high drug loading (some can even reach 100%); precisely adjustable drug loading quantification; no long-term toxicity induced by the carrier, etc.

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

The present invention aims to develop a technique for measuring neutrophil counts using small amounts of blood, such as 1 μL or less, as obtained by fingertip puncture. [Solution] A method for measuring the number of neutrophils in a blood sample is provided, which includes measuring superoxide anions in the presence of bortezomib or ixazomib or a salt thereof.

Provided herein are methods and uses for treating multiple myeloma (such as Newly Diagnosed Multiple Myeloma) in a patient in need thereof. The methods comprise administering to the patient an anti-CD38 antibody, bortezomib, lenalidomide, and dexamethasone.

The present invention relates to the preparation and application of a copper chalcogenide nanohydrogel. In this study, a copper chalcogenide nanocomposite system with high stability was successfully synthesized, and experiments were carried out in vitro and in vivo using this nanosystem to explore its application in the field of bladder cancer treatment, providing a new strategy to address the current limitations in bladder cancer treatment. The Cu<subgt;2-x< / subgt;Se@PDA@BTZ nanomaterial was prepared by a one-pot method. Through the surface modification of Cu<subgt;2-x< / subgt>Se with PDA, Cu<subgt;2-x< / subgt>Se was encapsulated inside PDA. In addition, bortezomib (BTZ) can be connected to PDA through a phenylboronic ester bond. At the same time, the PDA in the coating layer of the composite material can crosslink with tetra-armed polyethylene glycol-thiol (4ARM-PEG-SH) to form a nanohydrogel, which can prolong the retention time of the copper chalcogenide nanocomposite nanomaterial in the bladder, enhance the contact time between the bladder mucosa and the drug, play a drug sustained-release role, and achieve the efficient utilization of the drug.